2015 American Transplant Congress
Evaluation of Medication Regimen Complexity Over Time Following Heart Re-Transplantation
Medication regimen complexity (MRC) includes many characteristics of a drug regimen. Previously, we showed that MRC is high and persists over time after primary heart…2015 American Transplant Congress
Kidney Transplant Function After Late Conversion to Belatacept (Nulojix®)
Introduction: In the long-term follow up of kidney transplants, chronic transplant nephropathy often in combination with CNI-toxicity is a major problem. With declining transplant function…2015 American Transplant Congress
No Pharmacokinetic Interaction Between Pantoprazole and Mycophenolic Acid in Renal Transplant Patents: A Randomized Crossover Study
Department of Nephrology, Charité University Hospital, Berlin, Germany.
Mycophenolic acid (MPA) is used as an immunosuppressive agent in renal transplant (tx) patients (pts). 2 formulations are on the market: The prodrug Mycophenolate-Mofetil (MMF)…2015 American Transplant Congress
Patient Self-Reported Adherence to and Perceptions Towards Immunosuppressive Medications at the Outpatient Renal Transplant Clinic at St. Joseph's Healthcare Hamilton (SJHH)
Objectives To gain insight into the immunosuppressant adherence of patients followed by the Outpatient Renal Transplant Clinic at St. Joseph's Healthcare Hamilton (SJHH) and to…2015 American Transplant Congress
CD52-Negative NK Cells Are Abundant in the Liver and Less Susceptible to Alemtuzumab Treatment
Background: T-cell depleting strategies have become an integral part of immunosuppressive regimens in organ transplantation. Alemtuzumab is a humanized monoclonal antibody against CD52, a cell-surface…2015 American Transplant Congress
Prospective Study of a Steroid Free, Low Dose Tacrolimus and Everolimus Combination Regimen in Kidney Transplant
Calcineurin(CNI) based therapy is the cornerstone of immunosuppresion(IS) after kidney transplant. However chronic nephrotoxicity from CNI as been implicated in post-transplant renal dysfunction. We hypothesized…2015 American Transplant Congress
Kidney Transplantation After Hematopoietic Cell Transplantation in Plasma Cell Dyscrasias
INTRODUCTION:The plasma cell dyscrasias (PCD) include a number of entities such as multiple myeloma (MM), primary amyloidosis (AL) and Monoclonal immunoglobulin deposition disease (MIDD). Hematopoietic…2015 American Transplant Congress
The Use of Eculizumab to Treat the Highly Sensitized Patient Awaiting Heart Transplant
Cedars-Sinai Heart Institute, Los Angeles, CA.
Purpose: Highly sensitized patients (pts) awaiting heart transplantation remain a significant challenge due to prolonged often prohibitive wait times for suitable organs and increased rejection…2015 American Transplant Congress
Everolimus Versus Mycophenolate for Recipients of Kidney Transplants from Expanded Criteria Donors (ECD) Receiving Anti-Thymocyte Globulin and Tacrolimus
Introduction: Recipients of kidneys recovered from expanded criteria donors are at higher risk to develop delayed graft function (DGF) and acute rejection (AR), leading to…2015 American Transplant Congress
CD28-Directed Therapy Prolongs Survival in a Non-Human Primate Kidney Transplant Model
Introduction. Costimulation blockade using belatacept has the potential to improve long-term renal function and reduce cardiovascular risk by avoiding calcineurin inhibitors, yet higher rates and…
American Transplant Congress abstracts